Claims for Patent: 8,920,812

Summary for Patent: 8,920,812

Title:	Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
Abstract:	The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide.
Inventor(s):	Haynes; Joel R. (Bozeman, MT)
Assignee:	Takeda Vaccines, Inc. (Bozeman, MT)
Application Number:	13/505,250
Patent Claims:	1. A chimeric virus-like particle comprising a lentivirus or an alpha-retrovirus Gag polypeptide and a respiratory syncytial virus F polypeptide. 2. The virus-like particle of claim 1, wherein the Gag polypeptide is from a simian immunodeficiency virus or a human immunodeficiency virus. 3. The virus-like particle of claim 1, wherein the Gag polypeptide is from an avian leukosis virus or rous sarcoma virus. 4. The virus-like particle of claim 1, further comprising mammalian glycosylation. 5. The virus-like particle of claim 1, further comprising an adjuvant in admixture with the virus-like particle. 6. The virus-like particle of claim 5, wherein the adjuvant is located outside the virus-like particle. 7. The virus-like particle of claim 5, wherein the adjuvant is located inside the virus-like particle. 8. The virus-like particle of claim 5, wherein the adjuvant is covalently linked to the respiratory syncytial virus F polypeptide to form a covalent linkage. 9. The virus-like particle of claim 1, wherein a neutralizing anti-RSV-F antibody binds to the respiratory syncytial virus F polypeptide. 10. The virus-like particle of claim 9, wherein the neutralizing anti-RSV-F antibody is Palivizumab. 11. The virus-like particle of claim 1, further comprising an additional VLP-associating antigen. 12. The virus-like particle of claim 1, further comprising an additional VLP-associating polypeptide linked to a second antigen. 13. A method for producing a chimeric virus-like particle, comprising: (a) providing one or more expression vectors together which express a lentivirus or an alpha-retrovirus Gag polypeptide and a respiratory syncytial virus F polypeptide; (b) introducing the one or more expression vectors into a eukaryotic cell in a media; and (c) expressing the Gag polypeptide and the respiratory syncytial virus F polypeptide to produce the chimeric virus-like particle. 14. The method of claim 13, wherein the eukaryotic cell is a yeast cell, a mammalian cell, or an insect cell. 15. The method of claim 13, wherein the eukaryotic cell is a mammalian cell. 16. The method of claim 13, further comprising the step of recovering the virus-like particle from the media in which the eukaryotic cell is cultured. 17. The method of claim 13, wherein the expression vector is a viral vector. 18. The method of claim 17, wherein the viral vector is selected from the group consisting of: an adenovirus, a herpesvirus, a poxvirus and a retrovirus. 19. The method of claim 17, wherein the viral vector further includes a transcriptional regulator that down-regulates expression of the respiratory syncytial virus F polypeptide when the viral vector is propagated in a helper cell or up-regulates expression of the respiratory syncytial virus F polypeptide in the eukaryotic cell. 20. The method of claim 19, wherein the transcriptional regulator is a tet repressor or a metallothionine inducible enhancer. 21. The method of claim 13, wherein the eukaryotic cell is selected from the group consisting of a BHK cell, a VERO cell, an HT1080 cell, an MRC-5 cell, a WI 38 cell, an MDCK cell, an MDBK cell, an HEK293 cell, a 293T cell, an RD cell, a COS-7 cell, a CHO cell, a PER.C6 (TM) cell, a Jurkat cell, a HUT cell, a SUPT cell, a C8166cell, a MOLT4/clone8 cell, an MT-2 cell, an MT-4 cell, an H9 cell, a PM1 cell, a CEM cell, a myeloma cell, SB20 cell, a LtK cell, a HeLa cell, a WI-38 cell, an L2 cell, a CMT-93, and a CEMX174 cell. 22. A method for treating or preventing respiratory syncytial virus infection comprising administering to a subject an immunogenic amount of the virus-like particle of claim 1. 23. A pharmaceutical composition comprising an immunogenic amount of the virus-like particle of claim 1. 24. A method for providing protection against respiratory syncytial virus infection comprising administering to a subject an immunogenic amount of the virus-like particle of claim 1.

Details for Patent 8,920,812

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2029-11-03
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2029-11-03